JR-441
Sanfilippo Syndrome Type A (MPS IIIA)
Key Facts
About JCR Pharmaceuticals
JCR Pharmaceuticals has established itself as a premier global specialty pharmaceutical company focused on high-unmet-need rare diseases, particularly lysosomal storage disorders. Its strategic advantage is anchored in the proprietary J-Brain Cargo® platform, which enables targeted delivery of biologics across the blood-brain barrier—a key differentiator in treating neurological manifestations. The company has successfully commercialized products in multiple international markets and maintains a robust clinical pipeline, driving its significant market valuation. JCR's fully integrated model, from R&D to global commercialization, combined with a strong venture spirit, positions it for sustained growth in the orphan drug space.
View full company profileOther Sanfilippo Syndrome Type A (MPS IIIA) Drugs
| Drug | Company | Phase |
|---|---|---|
| UX111 | Abeona Therapeutics | Phase 1/2 |